Skip to content
10-K

Annual Report

PROPANC BIOPHARMA, INC. PPCB

0001493152-25-016069

← back to feed
Filed
Sep 29, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Sep 24, 2025 12.81M sh
Shares Diluted FY 2025 · Jun 30, 2025 3.97M sh
Shares Diluted restated FY 2025 · Jun 30, 2024 1.42K sh
Operating Cash Flow FY 2025 · Jun 30, 2025 −$405.17K
Operating Cash Flow FY 2025 · Jun 30, 2024 −$935.12K
Long Term Debt FY 2025 · Jun 30, 2025 $537.92K
Long Term Debt FY 2025 · Jun 30, 2024 $399.33K
Stockholders Equity FY 2025 · Jun 30, 2025 $13.91M
Stockholders Equity FY 2025 · Jun 30, 2024 −$3.78M
Stockholders Equity FY 2025 · Jun 30, 2023 −$3.12M
Current Liabilities FY 2025 · Jun 30, 2025 $5.58M
Current Liabilities FY 2025 · Jun 30, 2024 $3.79M
Total Liabilities FY 2025 · Jun 30, 2025 $5.73M
Total Liabilities FY 2025 · Jun 30, 2024 $3.85M
Current Assets FY 2025 · Jun 30, 2025 $8.35M
Current Assets FY 2025 · Jun 30, 2024 $25.44K
Total Assets FY 2025 · Jun 30, 2025 $19.63M
Total Assets FY 2025 · Jun 30, 2024 $72.37K
Eps Diluted FY 2025 · Jun 30, 2025 −$14.85
Eps Diluted restated FY 2025 · Jun 30, 2024 −$1,420.53
Eps Basic FY 2025 · Jun 30, 2025 −$14.85
Eps Basic restated FY 2025 · Jun 30, 2024 −$1,420.53
Sga Expense FY 2025 · Jun 30, 2025 $57.03M
Sga Expense FY 2025 · Jun 30, 2024 $1.25M
Rd Expense FY 2025 · Jun 30, 2025 $223.72K
Rd Expense FY 2025 · Jun 30, 2024 $248.1K
Net Income FY 2025 · Jun 30, 2025 −$58.92M
Net Income FY 2025 · Jun 30, 2024 −$1.82M
Operating Income FY 2025 · Jun 30, 2025 −$57.28M
Operating Income FY 2025 · Jun 30, 2024 −$1.54M